Akari Therapeutics to Attend Upcoming Investor Conferences in February
January 31 2017 - 6:00AM
Akari Therapeutics (NASDAQ:AKTX), an emerging growth,
clinical-stage biopharmaceutical company, announced today that
senior management will attend and host meetings at two upcoming
conferences.
- Canaccord Genuity 2017 Rare Disease, Biopharma One-on-One Day
on Tuesday, February 7, 2017 in New York, NY
- Leerink Partners 6th Annual Global Healthcare Conference on
February 16, 2017 in New York, NY
About Akari Therapeutics Plc
Akari is a clinical-stage biopharmaceutical company focused on
the development and commercialization of life-transforming
treatments for a range of rare and orphan autoimmune and
inflammatory diseases caused by dysregulation of complement C5 and
Leukotriene B4 (LTB4), including paroxysmal nocturnal
hemoglobinuria (“PNH”), atypical Hemolytic Uremic Syndrome
(“aHUS”), and Guillain Barré syndrome (“GBS”). Akari’s lead product
candidate, Coversin™ complement inhibitor, a second-generation
complement inhibitor, acts on complement component-C5, preventing
the release of C5a and the formation of C5b–9 (also known as the
membrane attack complex or MAC), and independently also inhibits
LTB4 activity. C5 inhibition is growing in importance in a range of
rare autoimmune diseases related to dysregulation of the complement
component of the immune system, including PNH, aHUS, and GBS.
Exploiting the power of nature, Akari is also developing other tick
derived proteins and expects to bring additional compounds to
clinical trials over the next several years. The pipeline is
focused on developing bioengineered versions of native tick
salivary proteins that act as anti-inflammatory compounds allowing
the tick to remain on its host. These compounds include PGP sparing
LTB4 inhibitors, classical and alternative complement inhibitors,
anti-histamines, and serotonin inhibitors as examples. Akari is
also developing engineered forms that allow for potential oral
absorption, as, for example, a potential orally absorbed C5
inhibitor, and tissue specific proteins, as, for example, Coversin™
that acts specifically at the neuromuscular junction for diseases
like myasthenia gravis.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control. Such risks and uncertainties for our company
include, but are not limited to: an inability or delay in obtaining
required regulatory approvals for Coversin and any other product
candidates, which may result in unexpected cost expenditures; risks
inherent in drug development in general; uncertainties in obtaining
successful clinical results for Coversin and any other product
candidates and unexpected costs that may result therefrom; failure
to realize any value of Coversin and any other product candidates
developed and being developed in light of inherent risks and
difficulties involved in successfully bringing product candidates
to market; inability to develop new product candidates and support
existing product candidates; the approval by the FDA and EMA and
any other similar foreign regulatory authorities of other competing
or superior products brought to market; risks resulting from
unforeseen side effects; risk that the market for Coversin may not
be as large as expected; inability to obtain, maintain and enforce
patents and other intellectual property rights or the unexpected
costs associated with such enforcement or litigation; inability to
obtain and maintain commercial manufacturing arrangements with
third party manufacturers or establish commercial scale
manufacturing capabilities; the inability to timely source adequate
supply of our active pharmaceutical ingredients from third party
manufacturers on whom the company depends; our inability to obtain
additional capital on acceptable terms, or at all; unexpected cost
increases and pricing pressures; uncertainties of cash flows and
inability to meet working capital needs; and risks and other risk
factors detailed in our public filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K filed
on March 23, 2016. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release and we
undertake no obligation to update or revise any of these statements
to reflect events or circumstances occurring after this press
release. We caution investors not to place considerable reliance on
the forward-looking statements contained in this press release.
Contact:
Investor Contact:
The Trout Group
Lee Stern
lstern@troutgroup.com
646–378–2922
Media Contact:
Susan Forman / Laura Radocaj
Dian Griesel Int'l.
(212) 825-3210
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2024 to May 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From May 2023 to May 2024